BridgeBio Pharma
Price & Volume
Stats
See more52W Range | $21.62-$44.32 |
Market Cap | $5B |
Shares Short | 16M |
Financials
See moreRevenue (12 Mos) | $217.7M |
Revenue Growth (YoY) | -33.2% |
Gross Profit (12 Mos) | $74.2M |
Diluted EPS | -$2.42 |
News
See moreYahoo Finance • 6 months ago
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance • 7 months ago
Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Yahoo Finance • 9 months ago
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Yahoo Finance • 10 months ago
BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe
About
CEO | Dr. Neil Kumar Ph.D. |
CFO | Dr. Brian C. Stephenson C.F.A., Ph.D. |
Address | 3160 Porter Drive, Palo Alto, CA, United States, 94304 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 550 |
